Relabelling or repackaging a medical device: scope the Article 16 assessment
Own branding, an intended-purpose change and a compliance-affecting modification raise different Article 16 questions from translation or necessary outer-packaging changes. Preserve a before-and-after evidence record, including the sterile barrier, before commissioning work. This guide prepares the assessment; it does not decide that a specific change qualifies for an exception.
Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.
Sourced criteria · EU
What changes the service scope?
Decision or task
What the source describes
What to prepare
What exactly changes, and who is named as manufacturer?
What the source describesArticle 16(1) addresses own-name marketing, intended-purpose changes and modifications that may affect compliance, with stated qualifications including a manufacturer agreement for the described branding context. [1]
What to prepareRecord the exact proposed branding, claims, physical changes and manufacturer identification. Separate unchanged supply from each change; provide agreements and artwork for a reviewed actor/obligation conclusion.
Is the original device condition preserved?
What the source describesArticle 16(2) describes translation/information and necessary outer-packaging changes under stated conditions. It specifically addresses adverse effects where sterile-maintaining packaging is opened, damaged or otherwise negatively affected. [1]
What to prepareMap outer packaging separately from the sterile-maintaining barrier. Photograph and document the process and affected layers; do not infer acceptability from a new carton or a generic packaging test.
Which controlled process and traceability records are needed?
What the source describesArticle 16(3) addresses identification of the activity/operator and quality procedures for accurate current translations, preserved original condition and manufacturer corrective-action information. [1]
What to preparePrepare a translation approval/version trail, repackaging controls, operator-identification examples and corrective-action handoff. Agree owners and evidence access rather than purchasing an unscoped label-editing service.
What notification and certification work must be assessed?
What the source describesFor the described paragraph 2 activities, Article 16(4) specifies advance manufacturer/authority information, samples or mock-ups on request and a notified-body quality-system certificate within the stated conditions. [1]
What to prepareHave the specialist confirm the actual route and current timing, then prepare the Member State, manufacturer, mock-up, relevant notified-body scope and submission evidence. Do not treat directory membership as certification.
This is a source-backed assessment brief for MDR Article 16, not an exception ruling or validation. Device status, the actual change, Member State, contracts, notified-body scope and current legal conditions remain unresolved; disputed or novel classifications require specialist review.
Use this evidence and handoff matrix
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
What exactly changes, and who is named as manufacturer?
Record the exact proposed branding, claims, physical changes and manufacturer identification. Separate unchanged supply from each change; provide agreements and artwork for a reviewed actor/obligation conclusion.
Useful evidence: Before/after artwork, claims, device configuration and manufacturer/distributor agreements.
Is the original device condition preserved?
Map outer packaging separately from the sterile-maintaining barrier. Photograph and document the process and affected layers; do not infer acceptability from a new carton or a generic packaging test.
Useful evidence: Packaging-layer diagrams, process steps, necessity rationale and original-condition/sterile-barrier assessment.
Which controlled process and traceability records are needed?
Prepare a translation approval/version trail, repackaging controls, operator-identification examples and corrective-action handoff. Agree owners and evidence access rather than purchasing an unscoped label-editing service.
Useful evidence: Translation/change-control records, process controls, activity identification and corrective-action communication procedure.
What notification and certification work must be assessed?
Have the specialist confirm the actual route and current timing, then prepare the Member State, manufacturer, mock-up, relevant notified-body scope and submission evidence. Do not treat directory membership as certification.
Useful evidence: A route/timing assessment, recipient list, mock-ups and dated relevant scope/certificate evidence.
Work packages and dependencies
Conditional: Relabelling or repackaging a medical device: scope the Article 16 assessment — Review the stated source/task matrix, actual deciding facts and evidence gaps. Agree the covered entities, products, deliverables, owners and exclusions before engagement.
Questions for providers
Which specific Article 16 route and qualifications fit the documented change?
Which layer or operation could affect the device or sterile condition, and what evidence resolves it?
Who approves each translated version and reconciles manufacturer safety changes?
Which notifications and certificate scope apply to this activity and who supplies the evidence?
Sources and data dates
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.